Several factors have been proposed as predictors of reactivation following anti VEGF therapy for ROP, including preretinal hemorrhage, anemia, sepsis, BW, and PMA at first treatment [21, 24–26]. This evidence concerns the gene VEGFA and anemia (phenotype).